Table 2 Summary of prior chemotherapy

From: A phase II study of S-1 monotherapy administered for 2 weeks of a 3-week cycle in advanced gastric cancer patients with poor performance status

 

Number of patients

Dose intensity

Treatment cycle

 

Total

CR-PR

SD

PD

Median (range)

Median (range)

Adjuvant

 Doxorubicin

13

   

1.00 (0.82–1.00)

12 (5–12)

 Taxanes

6

   

1.00 (0.73–1,00)

6 (5–9)

 Cisplatin

2

   

NA (0.84, 1.00)a

NA (8, 9)a

First-line

 Taxanes

19

5

10

4

1.00 (0.75–1.00)

6 (2–9)

 Cisplatin (±irinotecan)

5

2

3

—

0.94 (0.56–1.00)

6 (5–10)

 Capecitabine

2

2

—

—

NA (1.00, 0.93)a

NA (7, 9)a

 Irofulven

2

—

1

1

NA (1.00, 1.00)a

NA (2, 6)a

 Oxaliplatin

2

—

2

—

NA (0.98, 0.85)a

NA (8, 10)a

Second-line

 Taxanes

7

2

3

2

0.93 (0.58–1.00)

5 (2–9)

 Cisplatin (±irinotecan)

3

—

1

2

0.84 (0.49–0.89)

2 (2–6)

 Capecitabine

2

—

2

—

NA (0.94, 0.95)a

NA (4, 9)a

  1. CR=complete response; PD=progressive disease; PR=partial response; SD=stable disease.
  2. aMedian value was not obtainable due to small patient number (N=2).
Back to article page